Sphingolipids are multifaceted mediators in ovarian cancer [24], and the sphingosine kinase 1-sphingosine 1-phosphate receptor 1 axis is altered in ovarian cancer in multiple ways and therefore represents an attractive therapeutic target. This evidence concerns the gene SPHK1 and ovarian cancer.